Similar articles

• Residual HIV-1 disease in the era of highly active antiretroviral therapy.

  Pomerantz RJ. Pomerantz RJ. N Engl J Med. 1999 May 27;340(21):1672-4. doi: 10.1056/NEJM199905273402110. N Engl J Med. 1999. PMID: 10341281 No abstract available.
• Antiretrovirals for the heavily experienced patient: hefty plans to holidays.

  Martinez LJ. Martinez LJ. Res Initiat Treat Action. 1999 Oct;5(4):5-8. Res Initiat Treat Action. 1999. PMID: 11366942
• IL-2 taken to HAART.

  Gilden D. Gilden D. GMHC Treat Issues. 1999 Feb;13(2):4-6. GMHC Treat Issues. 1999. PMID: 11366116
• Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

  Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
• Pediatric antiretroviral therapy: from research to practice.

  Farley J, Vink P. Farley J, et al. Pediatr AIDS HIV Infect. 1996 Feb;7(1):9-13. Pediatr AIDS HIV Infect. 1996. PMID: 11361479 Review. No abstract available.